7UM Stock Overview
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ultimovacs ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.67 |
| 52 Week High | kr14.64 |
| 52 Week Low | kr0.48 |
| Beta | 1.01 |
| 1 Month Change | 6.01% |
| 3 Month Change | -94.41% |
| 1 Year Change | -93.96% |
| 3 Year Change | -88.91% |
| 5 Year Change | n/a |
| Change since IPO | -78.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7UM | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -14.6% | -5.9% | -1.7% |
| 1Y | -94.0% | -21.4% | -0.2% |
Return vs Industry: 7UM underperformed the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: 7UM underperformed the German Market which returned 0.9% over the past year.
Price Volatility
| 7UM volatility | |
|---|---|
| 7UM Average Weekly Movement | 33.7% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7UM's share price has been volatile over the past 3 months.
Volatility Over Time: 7UM's weekly volatility has increased from 19% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 26 | Carlos de Sousa | www.ultimovacs.com |
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA Fundamentals Summary
| 7UM fundamental statistics | |
|---|---|
| Market cap | €24.35m |
| Earnings (TTM) | -€16.12m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs 7UM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7UM income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr189.24m |
| Earnings | -kr189.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -5.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7UM perform over the long term?
See historical performance and comparison